About this policy
CMS National Coverage Determination | ncd_id=321 | manual_section=200.2 | coverage_level_code=2 | national_coverage_type=True | under_review=True | lab_ncd=False
Documentation requirements
Item/Service Description: A. General Lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma are characterized by airflow limitation that may be partially or completely reversible. Pharmacologic treatment with bronchodilators is used to prevent and/or control daily symptoms that may cause disability for persons with these diseases. These medications are intended to improve the movement of air into and from the lungs by relaxing and dilating the bronchial passageways. Beta adrenergic agonists are a commonly prescribed class of bronchodilator drug. They can be administered via nebulizer, metered dose inhaler, orally, or dry powdered inhaler. Nebulized beta adrenergic agonist with racemic albuterol has been used for many years. More recently, levalbuterol, the (R) enantiomer of racemic albuterol, has been used in some patient populations. There are concerns regarding the appropriate use of nebulized beta adrenergic agonist therapy for lung disease. Revision History: 12/2007 - Provided noncoverage policy. Effective date 09/10/2007. ( TN 79 ) (CR5820) Benefit Categories: 23 - Durable Medical Equipment Transmittal: transmittal_number=79 | transmittal_issue_date=2007-12-21 | change_request_number=5820
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.